Innovate for Today and Tomorrow
We are committed to providing best-in-class technology to help clinicians accurately diagnose
breast disease, such as breast cancer, through minimally invasive procedures.
Our goal is to help radiologists, surgeons and clinicians around the world make the breast cancer diagnostics process a quicker, easier and better.
Our goal is to deliver superior medical products and technologies that help clinicians accurately diagnose early stage breast cancer and breast disease through minimally invasive procedures that enhance clinical outcomes and the lives of women worldwide.
We will achieve this goal through our commitment to innovation, quality and education.
In 1995, Mammotome was introduced as the first vacuum-assisted biopsy system. Two years later, the Mammotome Biopsy System was acquired by Ethicon Endo-Surgery (EES), part of the Johnson & Johnson Family of Companies. EES continued to develop the Mammotome Biopsy System, creating additional image-guided products and developing the Mammotome brand into the worldwide market leader.
In July 2010, Devicor Medical Products, Inc. acquired the Breast Care Business from Ethicon Endo-Surgery. Devicor focuses exclusively on medical technologies that improve patient experiences and outcomes. Over the next several years, Devicor Medical launched two new innovative vacuum-assisted breast biopsy systems and acquired several other products to create a robust breast care product portfolio.
In December 2014, Devicor Medical Products was acquired by Leica Biosystems, part of the Danaher family of companies. Leica Biosystems is the global leader in anatomic pathology solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. The combination of the two companies uniquely positions us to develop integrated patient-to-pathology solutions for the diagnosis of cancer.
Headquartered in Cincinnati, Ohio, the Mammotome brand is sold in over 50 different countries throughout the world. Mammotome remains committed to its heritage of advancing technology for early detection of breast cancer, providing support and education for clinicians worldwide, and offering breast care information for patients.
To date, more than 5 million women worldwide have had a procedure using the minimally invasive Mammotome Biopsy System.
Enabling clinicians to efficiently provide patients a highly confident diagnosis within 24-hours from biopsy.
Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence.
In line with our Mission, we have established the following challenge for ourselves: Enable patients to get their diagnosis within 24 hours from biopsy. This is a goal we are striving towards, a goal that will guide our future strategies. This vision aims to decrease the time it takes from biopsy to patient diagnosis, to a 24 hour period. With a presence in every step of the workflow, no other company is positioned to streamline all these steps so that the whole process takes less than 24 hours.
Leica Biosystems is a global leader in workflow solutions and laboratory automation for anatomical pathology, bringing clinicians and researchers high workflow efficiency and confidence in cancer diagnostics. Leica Biosystems provides a comprehensive product range with easy-to-use and consistently reliable solutions, from sample preparation and staining to imaging and reporting. At Leica Biosystems, we value our customers as partners, and therefore strive to deliver excellence in everything we do.
Danaher is a global science and technology innovator committed to helping our customers solve complex challenges and improve quality of life worldwide. Our world class brands are leaders in some of the most demanding and attractive industries. A globally diverse team of 71,000 associates, we are united by our culture and operating system, the Danaher Business System, which is our competitive advantage. In 2014, we generated $19.9B in revenue and our market cap exceeded $60B. We are #149 on the Fortune 500 and our stock has outperformed the S&P 500 by more than 2,000% over 20 years.